Advertisement

Topics

New Pfizer EU approval offers first treatment option for leukaemia subtype

05:38 EDT 3 Jul 2017 | Pharmafile

Pfizer has revealed that its drug Besponsa (inotuzumab ozogamicin) has received approval from the European Commission as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), making it the first and only antibody drug conjugate (ADC) available for patients with this type of leukaemia in the EU.

read more

Original Article: New Pfizer EU approval offers first treatment option for leukaemia subtype

NEXT ARTICLE

More From BioPortfolio on "New Pfizer EU approval offers first treatment option for leukaemia subtype"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...